focus -WSS

focus

author：Wikipedia 2025-10-01 22:59:28 - browse：76854

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Data show record exodus of life scientists from academia

leisure time

WSS

Medicaid, Medicare dual

WHO recommends dropping component of many flu vaccines

Listen: Who gets the credit for GLP

Stanford president’s abrupt resignation sparks debate

US jobless claims fall again as labor market continues to flash strength

Mindstrong's demise and the future of mental health care

hotspot

focus

explore

Bright Health sells Medicare Advantage business to Molina

Did you have Obamacare on your GOP debate bingo card?

ChatGPT in medicine: STAT answers readers' burning questions

Why do women spend more than men on medical expenses?

Malaria cases in Florida and Texas: Here’s what you need to know

Address the ethical violations that led to 'Three Identical Strangers'

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mystery swirls around US soldier who entered North Korea days ago, officials say

New air purifier tech could be key to improving indoor air quality

Menendez indictment could see pharma lose a key ally

focus

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Address the ethical violations that led to 'Three Identical Strangers'

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Sudafed saga points to U.S. issues with evaluating older drugs

Health tech startups drop sharply from 2021 highs

Biogen shutters digital health group, ends Apple study, in cost cutting move

leisure time

leisure time

entertainment

hotspot